"Is this data as good as it appears ? More importantly tox profile looks best in class as well."

Efficacy data described in the AACR abstract seems very promising. More efficacy data is in the BIO-Europe slides from last week. I can't wait to see the AACR poster (maybe posted tomorrow) for more efficacy details. 

The safety data described in the AACR abstract for ZEN-3694 seems out of this world! This really does sound like it may be the best in class pan-BET inhibitor. To never have reached a maximally tolerated dose (MTD) is amazing! 

"ZEN-3694 dose levels ranged from 36 mg to 144 mg daily without reaching a MTD. The most common treatment-related adverse events (AEs) (any grade) included transient photophobia (66%), nausea (40%), fatigue (31%), decreased appetite (22%), and dysgeusia (16%). Grade ≥ 3 related AEs (N = 8) and dose-limiting toxicities (N = 1 at 96 mg dose level) were uncommon. No Grade ≥ 3 thrombocytopenia was observed. Exposure to ZEN-3694 increased with dose without significant drug-drug interaction with ENZ."

BearDownAZ